Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial

Context – Recent evidence suggests that treatment of mild‐to‐moderate Alzheimer's disease (AD) with atorvastatin provides significant benefit on the Alzheimer Disease Assessment Scale‐Cognitive (ADAS‐cog) after 6 months. Objective – To determine if benefit on ADAS‐cog performance produced by...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Acta neurologica Scandinavica 2006-08, Vol.114 (s185), p.3-7
Hauptverfasser:	Sparks, D. L., Connor, D. J., Sabbagh, M. N., Petersen, R. B., Lopez, J., Browne, P.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Alzheimer Disease - drug therapy Alzheimer Disease - genetics Alzheimer Disease - psychology Alzheimer's disease Apolipoproteins E - genetics Atorvastatin Calcium Cholesterol - blood clinical benefit Cognition Disorders - blood Cognition Disorders - drug therapy Cognition Disorders - etiology Double-Blind Method Female Heptanoic Acids - therapeutic use Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Male Neuropsychological Tests pharmaco-genetics Pyrroles - therapeutic use Severity of Illness Index Treatment Outcome treatment trial
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!